Drug Repositioning Strategies: Innovative strategies to boost pipeline productivity

Drug repositioning is regarded as the pharma industry’s solution to falling R&D productivity and weakening product pipelines, successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have enabledinnovative companies to adopt lower risk strategies to optimize product pipelines.

Drug Repositioning Strategies is a new report that provides in-depth analysis of leading pharma companies that are using novel technologies to reposition failed, marketed or reformulated compounds. This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them, enabling you to understand trends in the market and optimize your R&D pipeline. Use this report to examine current approaches to drug repositioning and identify successful technologies and business models that can help your organization deliver enhanced clinical and commercial output.

Read more...

• Obesity Drug Markets (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)

• Innovations in CNS (15/05/2008)
• Protein Engineering & Drug Design (14/05/2008)
• Winning Product Launch Strategies (14/05/2008)

• Outlook for RNAi (14/05/2008)
• Targeted Cancer Therapies (14/05/2008)
• The Future of Biosimilars (14/05/2008)
• Cardiovascular Disease Management (14/05/2008)
• Nanotechnology (12/05/2008)
• The Future of Targeted Therapeutics (12/05/2008)
• Nosocomial Vaccines (12/05/2008)
• HRT for Menopausal Symptoms (12/05/2008)
• CNS Market Overview (12/05/2008)

---